Trials / Completed
CompletedNCT00988494
Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Santen Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DE-105 ophthalmic solution | Topical ocular application |
| DRUG | DE-105 ophthalmic solution | Topical ocular application |
| DRUG | Placebo ophthalmic solution | Topical ocular application |
Timeline
- Start date
- 2009-09-01
- First posted
- 2009-10-02
- Last updated
- 2012-11-22
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00988494. Inclusion in this directory is not an endorsement.